Anixa Biosciences (ANIX) AI Stock Analysis

• Market Cap: $110.48M
• Dividend Yield: N/A
• Average Volume (3M): 430.17K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.53
• Revenue Growth: N/A
• EPS Growth: 11.78%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.39
• Shares Outstanding: 33,376,690
• 10 Day Avg. Volume: 212,548
• 30 Day Avg. Volume: 430,172
• PEG Ratio: 0.96
• Price to Book (P/B): 8.84
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -18.69
• Enterprise Value/Market Cap: 1.20
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -14.78K
• Enterprise Value/Ebitda: -11.37
• 1Y Price Target: $14.00
• Price Target Upside: 343.04% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.33
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: ―

Anixa Biosciences faces significant financial challenges, primarily due to its inability to generate revenue and persistent losses, which are compounded by negative cash flows. While its technical indicators show some positive momentum, the negative P/E ratio and lack of dividends make valuation unattractive. The company's financial performance is the primary concern, overshadowing technical and valuation aspects.

Positive Factors

Intellectual Property Expansion

The expansion of Anixa's patent portfolio in China strengthens its competitive position and potential for future commercialization in a major market.

Innovative Cancer Treatments

Advancing to Phase 2 trials indicates progress in developing innovative cancer treatments, which could lead to new revenue streams if successful.

Strong Equity Position

A strong equity position provides financial stability and flexibility, allowing Anixa to invest in R&D and pursue strategic opportunities.

Negative Factors

Negative Cash Flows

Persistent negative cash flows challenge liquidity and sustainability, potentially limiting the company's ability to fund ongoing operations and growth.

Revenue Generation Challenges

The inability to generate revenue highlights operational struggles, impacting long-term financial health and necessitating successful project commercialization.

Persistent Losses

Ongoing losses indicate operational inefficiencies and financial instability, requiring strategic changes to achieve profitability and sustain growth.

Anixa Biosciences Business Overview & Revenue Model

Company Description

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

How the Company Makes Money

Anixa Biosciences generates revenue primarily through partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These strategic partnerships often involve joint development efforts and shared access to proprietary technologies or compounds. Additionally, Anixa may receive milestone payments and royalties based on the successful development and commercialization of products that utilize its technologies. The company's revenue can also be supplemented by government or private research grants aimed at advancing its scientific endeavors. However, as a company focused on research and development, significant revenue generation is typically reliant on the successful advancement and commercialization of its projects.

Anixa Biosciences Financial Statement Overview

Summary

Anixa Biosciences is facing considerable financial challenges. The lack of revenue and persistent losses are significant issues, compounded by negative cash flows. While the balance sheet shows low leverage and a strong equity position, the company's inability to generate positive income and cash flows presents substantial risk going forward. Improvements in operational efficiency and revenue generation are crucial for future financial health.

Income Statement

Anixa Biosciences has faced significant challenges in generating revenue, with a complete drop to zero in the most recent year. The company has consistently experienced negative EBIT and net income, indicating ongoing operational and profitability issues. The lack of revenue growth and persistent losses highlight the company's struggles in achieving financial stability.

Balance Sheet

The company's balance sheet shows a relatively strong equity position compared to its liabilities, with a low debt-to-equity ratio, indicating low financial leverage. However, the continued negative net income affects the return on equity, which remains poor. The high equity ratio suggests financial stability, but the lack of profitability is a concern.

Cash Flow

Anixa Biosciences demonstrates negative operating and free cash flows, which is a concern for liquidity and sustainability. The company has managed to secure financing to cover its cash outflows, but the inability to generate positive cash flows from operations remains a significant weakness.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	210.00K	0.00	512.00K
Gross Profit	-36.00K	-37.00K	49.00K	0.00	127.00K
EBITDA	-11.70M	-12.66M	-10.96M	-13.73M	-13.08M
Net Income	-10.93M	-12.55M	-9.81M	-13.60M	-12.95M
Balance Sheet
Total Assets	16.08M	21.59M	25.52M	30.41M	36.26M
Cash, Cash Equivalents and Short-Term Investments	15.17M	19.92M	23.84M	29.69M	35.73M
Total Debt	204.00K	232.00K	175.00K	221.00K	259.00K
Total Liabilities	2.13M	2.70M	2.15M	2.21M	1.49M
Stockholders Equity	15.16M	20.00M	24.34M	29.05M	35.44M
Cash Flow
Free Cash Flow	-7.17M	-7.33M	-6.21M	-6.49M	-4.94M
Operating Cash Flow	-7.17M	-7.33M	-6.21M	-6.49M	-4.94M
Investing Cash Flow	4.87M	4.28M	-5.60M	-10.73M	-3.92M
Financing Cash Flow	2.28M	3.42M	366.00K	452.00K	31.57M

Anixa Biosciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.16
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANIX, the sentiment is Neutral. The current price of 3.16 is below the 20-day moving average (MA) of 3.27, below the 50-day MA of 3.94, and below the 200-day MA of 3.37, indicating a neutral trend. The MACD of -0.20 indicates Negative momentum. The RSI at 43.76 is Neutral, neither overbought nor oversold. The STOCH value of 36.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ANIX.

Anixa Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CSBR	55 Neutral	$99.70M	43.15	102.74%	―	9.06%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OKYO	51 Neutral	$106.44M	-20.79	―	―	―	―
CTNM	50 Neutral	$429.59M	-5.21	-30.40%	―	―	-100.71%
ANIX	49 Neutral	$110.48M	-9.83	-62.16%	―	―	11.78%
ATOS	45 Neutral	$77.76M	-2.57	-48.89%	―	―	-9.42%

Anixa Biosciences Corporate Events

Anixa Biosciences Reports Positive Phase 1 Trial Results

On December 11, 2025, Anixa Biosciences announced positive final data from its Phase 1 clinical trial of an investigational breast cancer vaccine, presented at the 2025 San Antonio Breast Cancer Symposium. The trial, conducted with Cleveland Clinic and funded by the U.S. Department of Defense, showed the vaccine met all primary endpoints, was safe, well-tolerated, and elicited immune responses in 74% of participants. These results support the advancement to Phase 2, with plans for a combination study with Keytruda in newly diagnosed breast cancer patients.

The most recent analyst rating on (ANIX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Anixa Biosciences stock, see the ANIX Stock Forecast page.